Global Information
회사소개 | 문의 | 비교리스트

세계의 동반진단 시장 : 기술 종류별, 적응증별 기회 분석과 산업 예측(2019-2026년)

Companion Diagnostics Market by Technology Type, and Indication: Global Opportunity Analysis and Industry Forecast, 2019-2026

리서치사 Allied Market Research
발행일 2019년 07월 상품 코드 908539
페이지 정보 영문 199 Pages
가격
US $ 3,840 ₩ 4,512,000 Excel by E-mail (Data Pack)
US $ 5,370 ₩ 6,310,000 PDF by E-mail (Single User License) help
DRM(디지털 저작권 관리 시스템) 장착 PDF 파일로, 1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste 가 되지 않으며, 인쇄는 1회에 한해 가능합니다. 인쇄물 이용은 PDF 라이선스 소유자로 한정됩니다.
US $ 6,450 ₩ 7,580,000 PDF by E-mail (5-user License) help
DRM(디지털 저작권 관리 시스템) 장착 PDF 파일로, 5명까지 이용할 수 있는 라이선스입니다. 인쇄는 5회까지 가능하며 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 8,995 ₩ 10,570,000 PDF by E-mail (Enterprise User License)

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



세계의 동반진단 시장 : 기술 종류별, 적응증별 기회 분석과 산업 예측(2019-2026년) Companion Diagnostics Market by Technology Type, and Indication: Global Opportunity Analysis and Industry Forecast, 2019-2026
발행일 : 2019년 07월 페이지 정보 : 영문 199 Pages

세계의 동반진단 시장은 2018년에 16억 7,800만 달러 규모에 달했으며, 2019년부터 18.3%의 CAGR로 성장하여 2026년까지 64억 5,200만 달러에 달할 것으로 예측됩니다.

세계의 동반진단(Companion Diagnostics) 시장을 다루었으며, 시장 성장 촉진요인과 시장 기회, 시장 동향, 기업 전략 등에 관한 광범위한 조사를 통해 상세한 시장 분석 및 향후 예측을 실시했습니다.

목차

제1장 서론

  • 보고서 개요
  • 이해관계자의 주요 이점
  • 주요 시장 부문
    • 주요 기업 리스트
  • 조사 방법
    • 2차 조사
    • 1차 조사
    • 해석 툴 및 모델

제2장 주요 요약

  • 조사 결과
  • 주요 조사 결과
    • 주요 투자 재원
    • 주요 영향요인
  • CXO의 견해

제3장 시장 개요

  • 시장 정의와 범위
  • 동반진단 산업/시장을 형성하는 주요 요소
    • 공급업체의 협상력 : 중
    • 신규 참여업체의 위협 : 고
    • 대체품의 위협 : 저
    • 경쟁사의 위협 : 중
    • 구매자의 협상력 : 중
  • 상부/유사 시장 개요
  • 시장 진화/산업 로드맵
  • 동반진단에 관한 정부 규제
  • 시장 역학
    • 성장 촉진요인
    • 성장 저해요인
    • 시장 기회
    • 영향 분석

제4장 기술별 시장

  • 개요
    • 시장 규모와 예측
  • 면역조직화학
    • 시장 규모와 예측 : 지역별
    • 시장 분석 : 국가별
  • 중합효소 연쇄 반응(PCR)
    • 시장 규모와 예측 : 지역별
    • 시장 분석 : 국가별
  • 차세대 시퀀싱(NGS)
    • 시장 규모와 예측 : 지역별
    • 시장 분석 : 국가별
  • ISH(In situ hybridization)
    • 시장 규모와 예측 : 지역별
    • 시장 분석 : 국가별
  • 기타
    • 시장 규모와 예측 : 지역별
    • 시장 분석 : 국가별

제5장 적응증별 시장

  • 개요
    • 시장 규모와 예측
  • 종양학
    • 주요 시장 동향과 기회
    • 시장 규모와 예측 : 종류별
    • 시장 규모와 예측
    • 시장 분석 : 국가별
  • 신경학
    • 시장 규모와 예측
    • 시장 분석 : 국가별
  • 기타
    • 시장 규모와 예측
    • 시장 분석 : 국가별

제6장 지역별 시장

  • 개요
    • 시장 규모와 예측
  • 북미
    • 주요 시장 동향, 성장 촉진요인, 기회
    • 시장 규모와 예측 : 국가별
    • 북미의 시장 규모와 예측 : 기술별
    • 북미의 시장 규모와 예측 : 적응증별
  • 유럽
    • 주요 시장 동향, 성장 촉진요인, 기회
    • 시장 규모와 예측 : 국가별
    • 유럽의 시장 규모와 예측 : 기술별
    • 유럽의 시장 규모와 예측 : 적응증별
  • 아시아태평양
    • 주요 시장 동향, 성장 촉진요인, 기회
    • 시장 규모와 예측 : 국가별
    • 아시아태평양의 시장 규모와 예측 : 기술별
    • 아시아태평양의 시장 규모와 예측 : 적응증별
  • 라틴아메리카, 중동 및 아프리카
    • 주요 시장 동향, 성장 촉진요인, 기회
    • 시장 규모와 예측 : 국가별
    • LAMEA의 시장 규모와 예측 : 기술별
    • LAMEA의 시장 규모와 예측 : 적응증별

제7장 경쟁 상황

  • 서론
    • 시장 기업 포지셔닝, 2018년
  • 주요 성공 전략
  • 경쟁 대시보드
  • 경쟁 히트맵

제8장 기업 개요

  • Abbott Laboratories Molecular, Inc.
  • Agilent(Dako Denmark A/S)
  • ARUP Laboratories, Inc.
  • BioMerieux
  • Danaher Corporation(Leica Microsystems)
  • Foundation Medicine, Inc.
  • Myriad Genetics, Inc.
  • Roche(Ventana Medical Systems, Inc)
  • Thermo Fisher Scientific(Life Technologies Corporation)
  • QIAGEN N.V.
KSM 19.09.04

List of Tables

  • TABLE 01. GLOBAL COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2026 ($MILLION)
  • TABLE 02. IMMUNOHISTOCHEMISTRY MARKET, BY REGION, 2018-2026 ($MILLION)
  • TABLE 03. POLYMERASE CHAIN REACTION MARKET, BY REGION, 2018-2026 ($MILLION)
  • TABLE 04. NEXT GENERATION SEQUENCING MARKET, BY REGION, 2018-2026 ($MILLION)
  • TABLE 05. IN SITU HYBRIDIZATION MARKET, BY REGION, 2018-2026 ($MILLION)
  • TABLE 06. OTHERS MARKET, BY REGION, 2018-2026 ($MILLION)
  • TABLE 07. GLOBAL COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2026 ($MILLION)
  • TABLE 08. COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TYPE, 2018-2026 ($MILLION)
  • TABLE 09. COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY REGION, 2018-2026 ($MILLION)
  • TABLE 10. COMPANION DIAGNOSTICS FOR NEUROLOGY MARKET, BY REGION, 2018-2026 ($MILLION)
  • TABLE 11. COMPANION DIAGNOSTICS FOR OTHERS MARKET, BY REGION, 2018-2026 ($MILLION)
  • TABLE 12. COMPANION DIAGNOSTICS MARKET REVENUE, BY REGION, 2018-2026 ($MILLION)
  • TABLE 13. NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2018-2026 ($MILLION)
  • TABLE 14. U.S. COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2026
  • TABLE 15. U.S. COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2026
  • TABLE 16. CANADA COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2026
  • TABLE 17. CANADA COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2026
  • TABLE 18. MEXICO COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2026
  • TABLE 19. MEXICO COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2026
  • TABLE 20. NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2026
  • TABLE 21. NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2026
  • TABLE 22. EUROPE COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2018-2026 ($MILLION)
  • TABLE 23. GERMONY COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2026
  • TABLE 24. GERMANY COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2026
  • TABLE 25. FRANCE COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2026
  • TABLE 26. FRANCE COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2026
  • TABLE 27. UK COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2026
  • TABLE 28. UK COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2026
  • TABLE 29. REST OF EUROPE COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2026
  • TABLE 30. REST OF EUROPE COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2026
  • TABLE 31. EUROPE COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2026
  • TABLE 32. EUROPE COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2026
  • TABLE 33. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2018-2026 ($MILLION)
  • TABLE 34. JAPAN COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2026
  • TABLE 35. JAPAN COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2026
  • TABLE 36. CHINA COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2026
  • TABLE 37. CHINA COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2026
  • TABLE 38. AUSTRALIA COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2026
  • TABLE 39. AUSTRALIA COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2026
  • TABLE 40. REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2026
  • TABLE 41. REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2026
  • TABLE 42. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2026
  • TABLE 43. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2026
  • TABLE 44. LAMEA COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2018-2026 ($MILLION)
  • TABLE 45. BRAZIL COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2026
  • TABLE 46. BRAZIL COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2026
  • TABLE 47. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2026
  • TABLE 48. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2026
  • TABLE 49. REST OF LAMEA COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2026
  • TABLE 50. REST OF LAMEA COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2026
  • TABLE 51. LAMEA COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2026
  • TABLE 52. LAMEA COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2026
  • TABLE 53. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 54. ABBOTT LABORATORIES: OPERATING SEGMENTS
  • TABLE 55. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 56. AGILENT: COMPANY SNAPSHOT
  • TABLE 57. AGILENT: OPERATING SEGMENTS
  • TABLE 58. AGILENT: PRODUCT PORTFOLIO
  • TABLE 59. ARUP LABORATORIES: COMPANY SNAPSHOT
  • TABLE 60. ARUP LABORATORIES: SERVICE PORTFOLIO
  • TABLE 61. BIOMERIEUX: COMPANY SNAPSHOT
  • TABLE 62. BIOMERIEUX: OPERATING SEGMENTS
  • TABLE 63. BIOMERIEUX: PRODUCT PORTFOLIO
  • TABLE 64. DANAHER CORPORATION: COMPANY SNAPSHOT
  • TABLE 65. DANAHER CORPORATION: OPERATING SEGMENTS
  • TABLE 66. DANAHER CORPORATION: PRODUCT PORTFOLIO
  • TABLE 67. FOUNDATION MEDICINE: COMPANY SNAPSHOT
  • TABLE 68. FOUNDATION MEDICINE: SERVICE PORTFOLIO
  • TABLE 69. MYRIAD GENETICS, INC: COMPANY SNAPSHOT
  • TABLE 70. MYRIAD GENETICS, INC: OPERATING SEGMENTS
  • TABLE 71. MYRIAD GENETICS, INC: PRODUCT PORTFOLIO
  • TABLE 72. ROCHE: COMPANY SNAPSHOT
  • TABLE 73. ROCHE: OPERATING SEGMENTS
  • TABLE 74. ROCHE: PRODUCT PORTFOLIO
  • TABLE 75. THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
  • TABLE 76. THERMO FISHER SCIENTIFIC: OPERATING SEGMENTS
  • TABLE 77. THERMO FISHER SCIENTIFIC: PRODUCT PORTFOLIO
  • TABLE 78. QIAGEN N.V: COMPANY SNAPSHOT
  • TABLE 79. QIAGEN N.V: OPERATING SEGMENTS
  • TABLE 80. QIAGEN N.V: PRODUCT PORTFOLIO

List of Figures

  • FIGURE 01. TOP INVESTMENT POCKETS IN THE GLOBAL COMPANION DIAGNOSTICS MARKET
  • FIGURE 02. TOP IMPACTING FACTORS
  • FIGURE 03. COMPANION DIAGNOSTICS MARKET SEGMENTATION
  • FIGURE 04. MARKET EVOLUTION/ INDUSTRY ROADMAP
  • FIGURE 05. IMPACT ANALYSIS
  • FIGURE 06. COMPARATIVE ANALYSIS OF IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
  • FIGURE 07. COMPARATIVE ANALYSIS OF POLYMERASE CHAIN REACTION MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
  • FIGURE 08. COMPARATIVE ANALYSIS OF NEXT GENERATION SEQUENCING MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
  • FIGURE 09. COMPARATIVE ANALYSIS OF IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
  • FIGURE 10. COMPARATIVE ANALYSIS OF OTHERS MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
  • FIGURE 11. COMPARATIVE ANALYSIS OF COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
  • FIGURE 12. COMPARATIVE ANALYSIS OF COMPANION DIAGNOSTICS FOR NEUROLOGY MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
  • FIGURE 13. COMPARATIVE ANALYSIS OF COMPANION DIAGNOSTICS FOR OTHERS MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
  • FIGURE 14. MARKET PLAYER POSITIONING, 2018
  • FIGURE 15. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2019* (%)
  • FIGURE 16. TOP WINNING STRATEGIES, BY COMPANY, 2018-2019*
  • FIGURE 17. COMPETITIVE DASHBOARD
  • FIGURE 18. COMPETITIVE HEATMAP OF KEY PLAYERS
  • FIGURE 19. ABBOTT LABORATORIES: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 20. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 21. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2018 (%)
  • FIGURE 22. AGILENT: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 23. AGILENT: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 24. AGILENT: REVENUE SHARE BY REGION, 2018 (%)
  • FIGURE 25. BIOMERIEUX: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 26. BIOMERIEUX: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 27. BIOMERIEUX: REVENUE SHARE BY REGION, 2018 (%)
  • FIGURE 28. DANAHER CORPORATION: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 29. DANAHER CORPORATION: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 30. DANAHER CORPORATION: REVENUE SHARE BY REGION, 2018 (%)
  • FIGURE 31. MYRIAD GENETICS, INC: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 32. MYRIAD GENETICS, INC: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 33. ROCHE NET SALES, 2016-2018 ($MILLION)
  • FIGURE 34. ROCHE: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 35. ROCHE: REVENUE SHARE BY REGION, 2018 (%)
  • FIGURE 36. THERMO FISHER SCIENTIFIC: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 37. THERMO FISHER SCIENTIFIC: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 38. THERMO FISHER SCIENTIFIC: REVENUE SHARE BY REGION, 2018 (%)
  • FIGURE 39. QIAGEN N.V: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 40. QIAGEN N.V: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 41. QIAGEN N.V: REVENUE SHARE BY REGION, 2018 (%)

The global companion diagnostics market generated $1,678 million in 2018, and is projected to reach $6,452 million by 2026, growing at a CAGR of 18.3% from 2019 to 2026.

Companion diagnostic is a medical device, often an in-vitro device that provides information essential for the safe and effective use of a corresponding drug or biological product. These tests help a health care professional to determine patients who can benefit from a particular therapeutic product, identify patients at increased risk of severe side effects as a result of the treatment with a particular therapeutic product as well as achieve improved safety or effectiveness.

The companion diagnostics market is expected to experience significant growth during the forecast period owing to growth in demand for advanced therapies, rise in R&D activities to develop low cost & highly efficient drugs, increase in awareness in personalized medicines and surge in demand for cost effective diagnosis are some factors that majorly drive the market growth.

The global companion diagnostics market is segmented based on technology, indication, and region. Based on technology, the market is categorized as immunohistochemistry, polymerase chain reaction (PCR), next Generation Sequencing (NGS), in situ hybridization, and others. On the basis of indication, it is segmented into oncology, neurology, and others. Oncology is further classified into lung cancer, colorectal cancer, breast cancer, blood cancer, and others. Based on region, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, and rest of Europe), Asia-Pacific (China, Japan, Australia, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa and rest of LAMEA).

KEY BENEFITS FOR STAKEHOLDERS

  • The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
  • A comprehensive analysis of all the regions is provided to determine the existing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.

KEY MARKET SEGMENTS

By Technology Type

  • Immunohistochemistry
  • Polymerase chain reaction (PCR)
  • Next Generation Sequencing (NGS)
  • In situ hybridization
  • Others
  • Indication
  • Oncology
  • Lung cancer
  • Colorectal cancer
  • Breast cancer
  • Blood cancer
  • Others
  • Neurology
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Africa
    • Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT

  • Abbott Laboratories Molecular, Inc.
  • Agilent (Dako Denmark A/S)
  • ARUP Laboratories, Inc.
  • BioMerieux SA
  • Danaher Corporation (Leica Microsystems)
  • Foundation Medicine, Inc.
  • Myriad Genetics, Inc.
  • Qiagen N.V.
  • Roche (Ventana Medical Systems, Inc.)
  • Thermo Fisher Scientific (Life Technologies Corporation)

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)

  • Resonance Health Ltd

Table of Contents

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key benefits for stakeholders
  • 1.3. Key market segments
    • 1.3.1. List of key players profiled in the report
  • 1.4. Research methodology
    • 1.4.1. Secondary research
    • 1.4.2. Primary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. Key findings of the study
  • 2.2. Key findings
    • 2.2.1. Top investment pockets
    • 2.2.2. Top impacting factors
  • 2.3. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key forces shaping companion diagnostics industry/market
    • 3.2.1. Moderate power of suppliers
    • 3.2.2. High threat of new entrants
    • 3.2.3. Low threat of substitution
    • 3.2.4. Moderate competitive rivalry
    • 3.2.5. Moderate power of buyers
  • 3.3. Parent/ peer market overview
  • 3.5. Market evolution/industry roadmap
  • 3.6. Government regulations for companion diagnostics
  • 3.7. Market dynamics
    • 3.7.1. Drivers
      • 3.7.1.1. Increased popularity of personalized medicine
      • 3.7.1.2. Increase in cases of adverse drug reactions (ADRs)
      • 3.7.1.3. Surge in healthcare expenditure worldwide
      • 3.7.1.4. Technological advancements in diagnostic techniques
    • 3.7.2. Restraints
      • 3.7.2.1. Unfavorable reimbursement policies in some countries
    • 3.7.3. Opportunities
      • 3.7.3.1. Growth opportunities in emerging markets
      • 3.7.3.2. Increase in incidence of cancer across the globe
    • 3.7.4. Impact analysis

CHAPTER 4: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Immunohistochemistry
    • 4.2.1. Market size and forecast, by region
    • 4.2.2. Market analysis, by country
  • 4.3. Polymerase chain reaction (PCR)
    • 4.3.1. Market size and forecast, by region
    • 4.3.2. Market analysis, by country
  • 4.4. Next generation sequencing (NGS)
    • 4.4.1. Market size and forecast, by region
    • 4.4.2. Market analysis, by country
  • 4.5. In situ hybridization
    • 4.5.1. Market size and forecast, by region
    • 4.5.2. Market analysis, by country
  • 4.6. Others
    • 4.6.1. Market size and forecast, by region
    • 4.6.2. Market analysis, by country

CHAPTER 5: COMPANION DIAGNOSTICS MARKET, BY INDICATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Oncology
    • 5.2.1. Key market trends and opportunities
    • 5.2.2. Market size and forecast, by type
      • 5.2.2.1. Lung cancer
      • 5.2.2.1.1. Market size and forecast
      • 5.2.2.2. Colorectal cancer
      • 5.2.2.2.1. Market size and forecast
      • 5.2.2.3. Breast cancer
      • 5.2.2.3.1. Market size and forecast
      • 5.2.2.4. Blood cancer
      • 5.2.2.4.1. Market size and forecast
      • 5.2.2.5. Others
      • 5.2.2.5.1. Market size and forecast
    • 5.2.3. Market size and forecast
    • 5.2.4. Market analysis, by country
  • 5.3. Neurology
    • 5.3.1. Market size and forecast
    • 5.3.2. Market analysis, by country
  • 5.4. Others
    • 5.4.1. Market size and forecast
    • 5.4.2. Market analysis, by country

CHAPTER 6: COMPANION DIAGNOSTICS MARKET, BY REGION

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. North America
    • 6.2.1. Key market trends, growth factors, and opportunities
    • 6.2.2. Market size and forecast, by country
      • 6.2.2.1. U.S.
      • 6.2.2.1.1. U.S. companion diagnostics market, by technology
      • 6.2.2.1.2. U.S. companion diagnostics market, by indication
      • 6.2.2.2. Canada
      • 6.2.2.2.1. Canada companion diagnostics market, by technology
      • 6.2.2.2.2. Canada companion diagnostics market, by indication
      • 6.2.2.3. Mexico
      • 6.2.2.3.1. Mexico companion diagnostics market, by technology
      • 6.2.2.3.2. Mexico companion diagnostics market, by indication
    • 6.2.3. North America market size and forecast, by technology
    • 6.2.4. North America Market size and forecast, by indication
  • 6.3. Europe
    • 6.3.1. Key market trends, growth factors, and opportunities
    • 6.3.2. Market size and forecast, by country
      • 6.3.2.1. Germany
      • 6.3.2.1.1. Germany companion diagnostics market, by technology
      • 6.3.2.1.2. Germany companion diagnostics market, by indication
      • 6.3.2.2. France
      • 6.3.2.2.1. France companion diagnostics market, by technology
      • 6.3.2.2.2. France companion diagnostics market, by indication
      • 6.3.2.3. UK
      • 6.3.2.3.1. UK companion diagnostics market, by technology
      • 6.3.2.3.2. UK companion diagnostics market, by indication
      • 6.3.2.4. Rest of Europe
      • 6.3.2.4.1. Rest of Europe companion diagnostics market, by technology
      • 6.3.2.4.2. Rest of Europe companion diagnostics market, by indication
    • 6.3.3. Europe market size and forecast, by technology
    • 6.3.4. Europe Market size and forecast, by indication
  • 6.4. Asia-Pacific
    • 6.4.1. Key market trends, growth factors, and opportunities
    • 6.4.2. Market size and forecast, by country
      • 6.4.2.1. Japan
      • 6.4.2.1.1. Japan companion diagnostics market, by technology
      • 6.4.2.1.2. Japan companion diagnostics market, by indication
      • 6.4.2.2. China
      • 6.4.2.2.1. China companion diagnostics market, by technology
      • 6.4.2.2.2. China companion diagnostics market, by indication
      • 6.4.2.3. Australia
      • 6.4.2.3.1. Australia companion diagnostics market, by technology
      • 6.4.2.3.2. Australia companion diagnostics market, by indication
      • 6.4.2.4. Rest of Asia-Pacific
      • 6.4.2.4.1. Rest of Asia-Pacific companion diagnostics market, by technology
      • 6.4.2.4.2. Rest of Asia-Pacific companion diagnostics market, by indication
    • 6.4.3. Asia-Pacific market size and forecast, by technology
    • 6.4.4. Asia-Pacific Market size and forecast, by indication
  • 6.5. LAMEA
    • 6.5.1. Key market trends, growth factors, and opportunities
    • 6.5.2. Market size and forecast, by country
      • 6.5.2.1. Brazil
      • 6.5.2.1.1. Brazil companion diagnostics market, by technology
      • 6.5.2.1.2. Brazil companion diagnostics market, by indication
      • 6.5.2.2. South Africa
      • 6.5.2.2.1. South Africa companion diagnostics market, by technology
      • 6.5.2.2.2. South Africa companion diagnostics market, by indication
      • 6.5.2.3. Rest of LAMEA
      • 6.5.2.3.1. Rest of LAMEA companion diagnostics market, by technology
      • 6.5.2.3.2. Rest of LAMEA companion diagnostics market, by indication
    • 6.5.3. LAMEA market size and forecast, by technology
    • 6.5.4. LAMEA Market size and forecast, by indication

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
    • 7.1.1. Market player positioning, 2018
  • 7.2. Top winning strategies
  • 7.3. Competitive dashboard
  • 7.4. Competitive heatmap

CHAPTER 8: COMPANY PROFILES

  • 8.1. Abbott Laboratories Molecular, Inc.
    • 8.1.1. Company overview
    • 8.1.2. Company snapshot
    • 8.1.3. Operating business segments
    • 8.1.4. Product portfolio
    • 8.1.5. Business performance
    • 8.1.6. Key strategic moves and developments
  • 8.2. Agilent (Dako Denmark A/S)
    • 8.2.1. Company overview
    • 8.2.2. Company snapshot
    • 8.2.3. Operating business segments
    • 8.2.4. Product portfolio
    • 8.2.5. Business performance
    • 8.2.6. Key strategic moves and developments
  • 8.3. ARUP Laboratories, Inc.
    • 8.3.1. Company overview
    • 8.3.2. Company snapshot
    • 8.3.3. Operating business segments
    • 8.3.4. Service portfolio
  • 8.4. BioMerieux
    • 8.4.1. Company overview
    • 8.4.2. Company snapshot
    • 8.4.3. Operating business segments
    • 8.4.4. Product portfolio
    • 8.4.5. Business performance
  • 8.5. Danaher Corporation (Leica Microsystems)
    • 8.5.1. Company overview
    • 8.5.2. Company snapshot
    • 8.5.3. Operating business segments
    • 8.5.4. Product portfolio
    • 8.5.5. Business performance
  • 8.6. Foundation Medicine, Inc.
    • 8.6.1. Company overview
    • 8.6.2. Company snapshot
    • 8.6.3. Operating business segments
    • 8.6.4. Service portfolio
    • 8.6.5. Key strategic moves and developments
  • 8.7. Myriad Genetics, Inc.
    • 8.7.1. Company overview
    • 8.7.2. Company snapshot
    • 8.7.3. Operating business segments
    • 8.7.4. Product portfolio
    • 8.7.5. Business performance
    • 8.7.6. Key strategic moves and developments
  • 8.8. Roche (Ventana Medical Systems, Inc)
    • 8.8.1. Company overview
    • 8.8.2. Company snapshot
    • 8.8.3. Operating business segments
    • 8.8.4. Product portfolio
    • 8.8.5. Business performance
    • 8.8.6. Key strategic moves and developments
  • 8.9. Thermo Fisher Scientific (Life Technologies Corporation)
    • 8.9.1. Company overview
    • 8.9.2. Company snapshot
    • 8.9.3. Operating business segments
    • 8.9.4. Product portfolio
    • 8.9.5. Business performance
    • 8.9.6. Key strategic moves and developments
  • 8.10. QIAGEN N.V.
    • 8.10.1. Company overview
    • 8.10.2. Company snapshot
    • 8.10.3. Operating business segments
    • 8.10.4. Product portfolio
    • 8.10.5. Business performance
    • 8.10.6. Key strategic moves and developments
Back to Top
전화 문의
F A Q